New hope for rare lung cancer mutations? dacomitinib under study
NCT ID NCT04504071
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing the targeted drug dacomitinib in 30 people with advanced non-small cell lung cancer that has uncommon EGFR mutations. Participants take a daily pill until their cancer worsens or side effects become too severe. The study aims to see how well the drug shrinks tumors and controls the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dacomitinib (a targeted cancer pill)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced lung cancer that has rare EGFR mutations, potentially shrinking tumors and delaying progression.
- What could go wrong
- This is a small, early-phase study with only 30 participants at one hospital, so results may not apply broadly. The drug may cause side effects or fail to control the cancer long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGF-R POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest hospital
Shanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple-drug cocktail re-sensitize lung cancer to treatment?
- Could a lung cancer drug designed for one mutation work for another?
- Could chemo plus immunotherapy double the punch against tough lung cancers?
- Should all advanced lung cancer patients get a brain scan? new trial aims to find out
- New hope for tough lung cancer? trial tests targeted drug against chemo
- New combo therapy for lung cancer under Real-World watch